Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology to SAFELY and EFFECTIVELY Vaccinate Children and Pregnant Women
April 08, 2021 09:00 ET
|
Generex Biotechnology Corp.; Last Chance for Children
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Last Chance for Children’s (LCFC) Mission is to help save children’s lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our...
Generex Biotechnology Announces Shareholder Conference Call Scheduled for Thursday May 6, 2021
March 31, 2021 11:03 ET
|
Generex Biotechnology Corp.
MIRAMAR, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB: GNBT) (“Generex or the “Company”), an innovative and integrated healthcare holding company with end-to-end...
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program
February 24, 2021 09:15 ET
|
Generex Biotechnology Corp.
Ii-Key-SARS-CoV-2 vaccine generates vaccine-specific antibodies and T cell responses in a transgenic mouse modelThe Ii-Key vaccine elicits both CD4+ T Helper cell (Th1) and CD8+ responses that are...
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM
February 03, 2021 09:00 ET
|
Generex Biotechnology Corp.
The access information for the investor conference call is as follows: Domestic US/Canada - 1-(866) 342-8588Direct Toll / International - 1-(203) 518-9865 Program Title: Generex Biotechnology...
Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM
January 08, 2021 14:23 ET
|
Generex Biotechnology Corp.
MIRAMAR, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5,...
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™
December 31, 2020 09:00 ET
|
Generex Biotechnology Corp.
The trademark application can be found at USPTO.gov by searching “Complete Vaccine” in the Trademark Electronic Search System (TESS)Ii-Key-SARS-CoV-2 vaccine enters GMP production for clinical...
Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand
November 23, 2020 08:30 ET
|
Generex Biotechnology Corp.
Memorandum of Understanding (MOU) signed by both partiesNegotiating final contract termsUpfront payment on closingLicensing fees, expenses, and price per dose to be determinedBintai Kinden Corporation...
Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine
November 19, 2020 08:30 ET
|
Generex Biotechnology Corp.
$2.5 million upfront for the Ii-Key-H1 vaccine from NuGenerex-Immuno-Oncology (NGIO) and to initiate epitope identification for Ii-Key vaccine development against the emerging swine flu in China G4EA...
Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform
November 18, 2020 08:30 ET
|
Generex Biotechnology Corp.
$50 million licensing deal for the Ii-Key platform to develop vaccines for infectious diseases and cancerDeal includes first contract for Ii-Key- SARS-CoV-2 vaccine against COVID-19 in China with a $5...
Generex Biotechnology Announces Interview with Richard Purcell EVP of R&D on the Yo! Dr.Yo Show with an Update on the Ii-Key COVID Vaccine Program
November 12, 2020 09:00 ET
|
Generex Biotechnology Corp.
MIRAMAR, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Richard Purcell, Executive Vice President of Research & Development at...